The science room · What I found and what I'd do about it

The science room.

I started with a simple question: what recurring skin problem could we solve honestly, distinctively and well enough to earn repeat use? The strongest development hypothesis is post-active recovery. This is a formula brief and proof plan—not a claim that we have already made or tested anything.

← Back to the brief · What I've been learning · The market research →

01 · The central finding

Cloudberry is the brand's soul—not its clinical proof.

Cloudberry gives Skírr its place, mood and point of view. Its fruit and seed contain interesting lipids and antioxidant compounds, and that makes it a credible supporting ingredient and a beautiful brand signature. But the published evidence I found is mainly composition and laboratory work—not a finished topical product proven on people's faces. That is why I would not say cloudberry brightens skin or make it carry our performance claim. See the cloudberry composition research ↗

“When my skin feels tight, hot or flaky after actives, give me a two-step reset that feels immediately comforting—and beautiful enough to keep within reach.”

That is the consumer job I think we should validate first. “Post-active recovery” is recognizable without asking Skírr to diagnose or treat disease. The serum floods skin with water-binding support; the cream seals with humectants, emollients, oat and a properly engineered lipid system.

The sentence above is a synthesized job-to-be-done, not a consumer quote or an approved product claim. We earn performance language only if the finished serum and cream pass the safety, stability and human-use program below.

02 · What I would formulate toward

Flood. Seal. Reset.

01 · Cloudberry + Oat Recovery Serum

Starting targets: glycerin 5–8%; panthenol 2%; ectoin 0.5–1%; oat beta-glucan 0.1–0.3%; cloudberry extract 0.3–0.5%; preservation, chelation and pH adjustment as required.

The job is immediate hydration and a cushioned, non-pilling feel. Human studies support topical dexpanthenol's role in hydration and barrier measures, and ectoine-containing finished products have clinical evidence in impaired-barrier populations. Those studies do not prove this future serum, so COSMAX should quote 0.5% and 1% ectoin prototypes and we should let finished-product testing decide. Review the dexpanthenol trial ↗ · Review the 1% ectoine finished-product trial ↗

Cloudberry and beta-glucan support identity, water-binding and feel; they do not carry the headline claim alone.

02 · Arctic Barrier Cream

Starting targets: colloidal oatmeal 1%; glycerin 5–8%; squalane 3–5%; panthenol 1–2%; cloudberry seed oil 0.5–1%; a ceramide/cholesterol/free-fatty-acid complex at the supplier-supported use level.

The physiological lipids must work as a system; poorly balanced mixtures can underperform. That means the formulation architecture matters more than simply putting “ceramides” on the label. Review the barrier-lipid study ↗

One-percent colloidal-oat finished products have human evidence for dry, irritated skin and barrier measures. That supports the concentration as a serious starting point—but it still does not prove a future Skírr cream. Review the randomized oat study ↗ · Review the oat barrier study ↗

The formulation rule: keep the ingredient list as short as the performance, preservation and sensory brief allow—not shorter. No fragrance, essential oils, added color or vague “Nordic berry complex.” “Natural” does not remove the need for an effective preservation system, chelator, emulsifier or pH control.

The packaging rule: keep the current birchwood visual system. Quote a standard high-quality pump for the serum before paying for airless. Keep the 50 ml cream jar only if an inner disc, compatibility work and challenge testing support it. Airless is a technical decision, not a brand requirement.

03 · The proof system

I would make the claim earn its way onto the page.

I would not jump from ingredient papers or a supplier deck to “clinically proven.” I would move in this order, on the finished formulas, with a qualified independent laboratory and regulatory review.

01

Prove the formula survives real life.

Complete accelerated and real-time stability, preservative challenge testing and package compatibility—including dispensing, leakage, weight loss, discoloration, odor and formula contact with every component. Stop or reformulate at any failed gate.

02

Establish tolerability.

Run a professionally supervised HRIPT under a defined repeated-exposure protocol, followed by an in-use facial tolerability study. HRIPT is useful evidence at the tested dose, but protocols vary and it does not prove daily facial comfort on its own. Read the HRIPT review ↗

03

Run a 28-day finished-product study.

Target 60–100 participants, with at least half self-reporting sensitive or reactive skin and deliberate Fitzpatrick I–VI representation. Measure at baseline, 30 minutes–24 hours, day 14 and day 28. Use corneometry for hydration; TEWL as a supportive barrier endpoint; investigator grading and standardized photography for dryness, flaking and roughness; and participant diaries for comfort, sting, finish, pilling and routine adherence.

Claims to earn: instant hydration; visibly less dry, flaky and rough skin; supports the moisture barrier; suitable for sensitive skin. Use only the language the finished-product data support. Avoid eczema, healing, disease-treatment and anti-inflammatory drug claims unless the product follows the appropriate regulatory pathway. Review FDA claim boundaries ↗

04 · A future research program—not a launch ingredient

Birch-bark triterpenes are interesting. They are not ours to claim.

Birch-bark triterpenes have serious clinical evidence, but that evidence belongs to Filsuvez, an FDA-approved prescription drug for wounds associated with certain forms of epidermolysis bullosa. The phase III study was about a regulated drug used on open wounds—not a barrier-reset cosmetic. Read the phase III study ↗ · See the FDA approval summary ↗

My rule: birch-bark triterpenes stay in a future research program only. Before they appear in any Skírr product, story or claim, we would need regulatory counsel, intellectual-property clearance, supplier documentation, cosmetic-use safety review and finished-product evidence. We cannot borrow a prescription drug's evidence for a cosmetic.

The same rule applies to every exciting laboratory paper: work in cells or a dish is a reason to investigate, not a reason to advertise.

05 · What I'd do next

Build the formula around the promise, then try to disprove it.

  1. Give COSMAX the written serum and cream targets above, including the required feel, no-pilling finish, ingredient exclusions, target pack and cost guardrail.
  2. Ask for the exact ingredient forms, concentrations, pH, preservation system, stability plan and evidence behind every proposed claim. “Proprietary complex” is not an answer.
  3. Make controlled prototypes where the evidence is uncertain: 0.5% versus 1% ectoin in the serum, and the selected lipid-complex level in the cream. Let performance and feel—not ingredient count—choose.
  4. Complete stability, package compatibility and challenge testing; then HRIPT and the 28-day finished-product study. Stop or reformulate at any failed gate.
  5. Do not place a meaningful purchase order or print a clinical claim until the formula, safety file and evidence all line up.

That is the science business I would want us to build: a beautiful Nordic world, a real customer problem and proof that is stronger than our copy.

← Back to the brief · What I've been learning · The market research →

Sources I would put in front of a chemist

The evidence behind this direction.

  1. Gehring W, Gloor M. Arzneimittelforschung. 2000;50(7):659–663. Randomized, double-blind vehicle-controlled human study of topical dexpanthenol and barrier/hydration measures.
  2. Alexopoulos A et al. Pediatric Dermatology. 2023;40(1):78–83. Randomized vehicle-controlled finished-product study using 1% ectoine plus 0.1% hyaluronic acid; evidence for the tested formula, not ectoin alone.
  3. Man MQ et al. Journal of Investigative Dermatology. 1996;106(5):1096–1101. Physiological lipid mixtures and barrier repair.
  4. Lisante TA et al. Journal of Dermatological Treatment. 2017;28(7):659–667. Randomized active-controlled study of a 1% colloidal-oat finished product; not evidence for Skírr.
  5. Capone K et al. Journal of Drugs in Dermatology. 2020;19(5):524–531. Human finished-product evidence on 1% colloidal oat, hydration and barrier measures.
  6. Cloudberry fruit and seed composition research. Useful for ingredient understanding and identity, not proof of a finished facial product.
  7. Bormann JL, Maibach HI. Regulatory Toxicology and Pharmacology. 2021;121:104867. Review of HRIPT methods, uses and limitations.
  8. FDA Cosmetics Labeling Claims. The boundary between cosmetic language and drug claims.
  9. Filsuvez phase III trial and FDA Drug Trials Snapshot. Prescription-drug evidence only; not cosmetic substantiation.